• Publications
  • Influence
The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease
TLDR
The workgroup sought to ensure that the revised criteria would be flexible enough to be used by both general healthcare providers without access to neuropsychological testing, advanced imaging, and cerebrospinal fluid measures, and specialized investigators involved in research or in clinical trial studies who would have these tools available.
Mild cognitive impairment – beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment
TLDR
A multidisciplinary, international group of experts discussed the current status and future directions of MCI, with regard to clinical presentation, cognitive and functional assessment, and the role of neuroimaging, biomarkers and genetics.
Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease
TLDR
A conceptual framework and operational research criteria are proposed, based on the prevailing scientific evidence to date, to test and refine these models with longitudinal clinical research studies and it is hoped that these recommendations will provide a common rubric to advance the study of preclinical AD.
The Alzheimer's disease neuroimaging initiative.
TLDR
The Alzheimer's Disease Neuroimaging Initiative will help identify clinical, neuroimaging, and biomarker outcome measures that provide the highest power for measurement of longitudinal changes and for prediction of transitions.
Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade
TLDR
This work proposes a model that relates disease stage to AD biomarkers in which Abeta biomarkers become abnormal first, before neurodegenerative biomarkers and cognitive symptoms, and neurodegnerative biomarker become abnormal later, and correlate with clinical symptom severity.
The Alzheimer's disease neuroimaging initiative (ADNI): MRI methods
TLDR
The approach taken in ADNI to standardization across sites and platforms of the MRI protocol, postacquisition corrections, and phantom‐based monitoring of all scanners could be used as a model for other multisite trials.
Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers
TLDR
It is speculated that the two major proteinopathies underlying AD biomarker changes, amyloid β (Aβ) and tau, might be initiated independently in sporadic AD, in which it is hypothesised that an incident Aβ pathophysiology can accelerate antecedent limbic and brainstem tauopathy.
NIA-AA Research Framework: Toward a biological definition of Alzheimer’s disease
TLDR
This research framework seeks to create a common language with which investigators can generate and test hypotheses about the interactions among different pathologic processes (denoted by biomarkers) and cognitive symptoms and envision that defining AD as a biological construct will enable a more accurate characterization and understanding of the sequence of events that lead to cognitive impairment that is associated with AD.
Automatic classification of MR scans in Alzheimer's disease.
TLDR
Assessment of support vector machines assigned individual diagnoses and whether data-sets combined from multiple scanners and different centres could be used to obtain effective classification of scans suggests an important role for computer based diagnostic image analysis for clinical practice.
The clinical use of structural MRI in Alzheimer disease
TLDR
The utility of structural imaging and other markers will be increased by standardization of acquisition and analysis methods, and by development of robust algorithms for automated assessment, as well as by research into other imaging and nonimaging markers.
...
1
2
3
4
5
...